To Cut Drug Costs, FDA Paves Way For Easier Approval Of Copycat Biologics

To Cut Drug Costs, FDA Paves Way For Easier Approval Of Copycat Biologics The draft framework announced Wednesday lowers the standards that companies need to meet to bring the drugs to market. Also, states try to lower drug prices by regulating PBMs; how the immigration crackdown is affecting elder care; and more. https://kffhealthnews.org/morning-breakout/to-cut-drug-costs-fda-paves-way-for-easier-approval-of-copycat-biologics/